A number of research firms have changed their ratings and price targets for Aridis Pharmaceuticals (NASDAQ: ARDS): 11/20/2018 – Aridis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of […]